Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
$2.33
+2.6%
$2.37
$0.85
$3.00
$448.25M2.0281,002 shs71,988 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$12.51
+0.2%
$9.92
$1.46
$12.80
$511.53M1.38567,389 shs870,408 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$6.26
+1.6%
$7.07
$5.12
$19.54
$476.45M0.691.45 million shs767,565 shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$15.80
-0.2%
$16.64
$6.52
$20.91
$430.08M2.17235,131 shs144,721 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
+2.64%+5.91%-6.80%-7.91%+104.39%
LifeMD, Inc. stock logo
LFMD
LifeMD
+0.16%+4.69%+23.49%+119.86%+714.98%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+1.62%+19.01%-10.32%-26.27%-60.65%
ZimVie Inc. stock logo
ZIMV
ZimVie
-0.19%-0.13%-9.20%-12.03%+104.93%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
0.0798 of 5 stars
0.82.00.00.00.61.70.6
LifeMD, Inc. stock logo
LFMD
LifeMD
0.3477 of 5 stars
1.54.00.00.01.80.80.0
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
1.0733 of 5 stars
3.31.00.00.02.00.80.6
ZimVie Inc. stock logo
ZIMV
ZimVie
0.5086 of 5 stars
0.85.00.00.03.01.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
1.67
Reduce$1.80-22.75% Downside
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$10.40-16.87% Downside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.60
Moderate Buy$18.00187.54% Upside
ZimVie Inc. stock logo
ZIMV
ZimVie
1.67
Reduce$16.001.27% Upside

Current Analyst Ratings

Latest ZIMV, TVTX, AVAH, and LFMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $19.00
4/23/2024
LifeMD, Inc. stock logo
LFMD
LifeMD
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $14.00
4/17/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$13.00
4/11/2024
ZimVie Inc. stock logo
ZIMV
ZimVie
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
3/27/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
3/18/2024
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$2.00 ➝ $3.00
3/15/2024
LifeMD, Inc. stock logo
LFMD
LifeMD
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $13.00
3/13/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00
3/5/2024
ZimVie Inc. stock logo
ZIMV
ZimVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderweight ➝ Underweight$13.00 ➝ $16.00
2/16/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $9.00
2/16/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$13.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
$1.90B0.24$0.59 per share3.94($0.68) per share-3.43
LifeMD, Inc. stock logo
LFMD
LifeMD
$152.55M3.35N/AN/A$0.15 per share83.40
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$145.24M3.28N/AN/A$2.67 per share2.34
ZimVie Inc. stock logo
ZIMV
ZimVie
$457.43M0.94$4.80 per share3.29$15.43 per share1.02

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
-$134.52M-$0.71N/AN/AN/A-7.10%N/A-1.86%5/9/2024 (Confirmed)
LifeMD, Inc. stock logo
LFMD
LifeMD
-$20.60M-$0.70N/AN/AN/A-14.01%N/A-50.74%5/8/2024 (Confirmed)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$111.40M-$1.61N/AN/AN/A-56.02%-177.97%-44.19%5/6/2024 (Confirmed)
ZimVie Inc. stock logo
ZIMV
ZimVie
-$393.28M-$14.81N/AN/A-51.33%2.44%1.08%5/8/2024 (Confirmed)

Latest ZIMV, TVTX, AVAH, and LFMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
-$0.0480N/A+$0.0480N/AN/AN/A  
5/8/2024N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.13N/A+$0.13N/AN/AN/A  
5/8/2024N/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/AN/A  
5/6/2024N/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.98N/A+$0.98N/AN/AN/A  
3/14/2024Q4 2023
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
-$0.04-$0.02+$0.02$0.09$464.33 million$478.84 million
3/11/2024Q4 2023
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.14-$0.12+$0.02-$0.12$40.65 million$44.86 million
2/28/2024Q4 2023
ZimVie Inc. stock logo
ZIMV
ZimVie
N/A$0.10+$0.10$12.79N/A$113.07 million
2/15/2024Q4 2023
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$1.27-$1.16+$0.11-$1.14$41.25 million$45.06 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
N/A
0.89
0.89
LifeMD, Inc. stock logo
LFMD
LifeMD
3.22
1.22
1.15
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
1.88
3.47
3.41
ZimVie Inc. stock logo
ZIMV
ZimVie
1.26
2.78
2.32

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
87.96%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
7.80%
LifeMD, Inc. stock logo
LFMD
LifeMD
18.89%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
3.75%
ZimVie Inc. stock logo
ZIMV
ZimVie
3.01%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
33,500192.38 million177.37 millionOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
20740.89 million33.16 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
38076.11 million73.26 millionOptionable
ZimVie Inc. stock logo
ZIMV
ZimVie
2,60027.22 million26.40 millionOptionable

ZIMV, TVTX, AVAH, and LFMD Headlines

SourceHeadline
ZimVie (ZIMV) Set to Announce Earnings on WednesdayZimVie (ZIMV) Set to Announce Earnings on Wednesday
marketbeat.com - May 1 at 7:40 AM
Dental Bone Graft Substitutes Market Worth $1.8 billion | MarketsandMarkets™Dental Bone Graft Substitutes Market Worth $1.8 billion | MarketsandMarkets™
finance.yahoo.com - April 30 at 11:22 AM
Short Interest in ZimVie Inc. (NASDAQ:ZIMV) Drops By 20.9%Short Interest in ZimVie Inc. (NASDAQ:ZIMV) Drops By 20.9%
americanbankingnews.com - April 28 at 1:34 AM
Restorative Dentistry Market Predicted to Reach USD 35 Billion by 2032 With 7.4% CAGRRestorative Dentistry Market Predicted to Reach USD 35 Billion by 2032 With 7.4% CAGR
pharmiweb.com - April 26 at 10:13 AM
(ZIMV) Technical Pivots with Risk Controls(ZIMV) Technical Pivots with Risk Controls
news.stocktradersdaily.com - April 26 at 10:13 AM
ZimVie to Report First Quarter Financial Results on May 8, 2024ZimVie to Report First Quarter Financial Results on May 8, 2024
globenewswire.com - April 24 at 4:05 PM
Whats going on in spinal tech?What's going on in spinal tech?
beckersspine.com - April 18 at 7:56 PM
ZimVie Closes Sale of Spine Business – Re-Named Highridge MedicalZimVie Closes Sale of Spine Business – Re-Named Highridge Medical
ryortho.com - April 15 at 6:50 PM
ZimVie (NASDAQ:ZIMV) Given Hold Rating at Needham & Company LLCZimVie (NASDAQ:ZIMV) Given Hold Rating at Needham & Company LLC
marketbeat.com - April 11 at 8:32 AM
ZimVie begets Highridge Medical with completed spine business spinoutZimVie begets Highridge Medical with completed spine business spinout
fiercebiotech.com - April 1 at 3:21 PM
Public company sells spine business to H.I.G. Capital for $375 millionPublic company sells spine business to H.I.G. Capital for $375 million
bizjournals.com - April 1 at 3:21 PM
H.I.G. Capital Acquires the Spine Business of ZimVie Rebranded as Highridge MedicalH.I.G. Capital Acquires the Spine Business of ZimVie Rebranded as Highridge Medical
finance.yahoo.com - April 1 at 10:21 AM
ZimVie Shares Rise 9% After Closing of Spine Business Sale for $375MZimVie Shares Rise 9% After Closing of Spine Business Sale for $375M
marketwatch.com - April 1 at 10:21 AM
ZimVie Announces Closing of Sale of Spine BusinessZimVie Announces Closing of Sale of Spine Business
globenewswire.com - April 1 at 8:00 AM
ZimVie to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceZimVie to Participate in the 23rd Annual Needham Virtual Healthcare Conference
globenewswire.com - March 27 at 8:00 AM
Multiple Reasons for the Surge of ZimVie (ZIMV) in Q4Multiple Reasons for the Surge of ZimVie (ZIMV) in Q4
finance.yahoo.com - March 15 at 8:10 AM
DeviceTalks and our team are finalists in the Software & Information Industry Association’s Neal AwardsDeviceTalks and our team are finalists in the Software & Information Industry Association’s Neal Awards
medicaldesignandoutsourcing.com - March 14 at 10:07 PM
5 medtech notes: Orthofix, ZimVie and more5 medtech notes: Orthofix, ZimVie and more
beckersspine.com - March 6 at 4:58 PM
One ZimVie Inc. (NASDAQ:ZIMV) Analyst Just Cut Their EPS ForecastsOne ZimVie Inc. (NASDAQ:ZIMV) Analyst Just Cut Their EPS Forecasts
finance.yahoo.com - March 3 at 8:10 AM
ZimVie Inc.: ZimVie Reports Fourth Quarter and Full Year 2023 Financial ResultsZimVie Inc.: ZimVie Reports Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 1 at 2:15 PM
ZimVie Inc. (ZIMV) Q4 2023 Earnings Call TranscriptZimVie Inc. (ZIMV) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 1 at 9:15 AM
ZimVie Full Year 2023 Earnings: EPS Misses ExpectationsZimVie Full Year 2023 Earnings: EPS Misses Expectations
finance.yahoo.com - March 1 at 9:15 AM
ZimVies 2023 spine sales fall 9% ahead of saleZimVie's 2023 spine sales fall 9% ahead of sale
beckersspine.com - February 29 at 2:45 PM
Q4 2023 ZimVie Inc Earnings CallQ4 2023 ZimVie Inc Earnings Call
finance.yahoo.com - February 29 at 9:44 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aveanna Healthcare logo

Aveanna Healthcare

NASDAQ:AVAH
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
LifeMD logo

LifeMD

NASDAQ:LFMD
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
Travere Therapeutics logo

Travere Therapeutics

NASDAQ:TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
ZimVie logo

ZimVie

NASDAQ:ZIMV
ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.